Potential and Therapeutic Efficacy of Cell-based Therapy Using Mesenchymal Stem Cells for Acute/chronic Kidney Disease
- PMID: 30939749
- PMCID: PMC6479813
- DOI: 10.3390/ijms20071619
Potential and Therapeutic Efficacy of Cell-based Therapy Using Mesenchymal Stem Cells for Acute/chronic Kidney Disease
Abstract
Kidney disease can be either acute kidney injury (AKI) or chronic kidney disease (CKD) and it can lead to the development of functional organ failure. Mesenchymal stem cells (MSCs) are derived from a diverse range of human tissues. They are multipotent and have immunomodulatory effects to assist in the recovery from tissue injury and the inhibition of inflammation. Numerous studies have investigated the feasibility, safety, and efficacy of MSC-based therapies for kidney disease. Although the exact mechanism of MSC-based therapy remains uncertain, their therapeutic value in the treatment of a diverse range of kidney diseases has been studied in clinical trials. The use of MSCs is a promising therapeutic strategy for both acute and chronic kidney disease. The mechanism underlying the effects of MSCs on survival rate after transplantation and functional repair of damaged tissue is still ambiguous. The paracrine effects of MSCs on renal recovery, optimization of the microenvironment for cell survival, and control of inflammatory responses are thought to be related to their interaction with the damaged kidney environment. This review discusses recent experimental and clinical findings related to kidney disease, with a focus on the role of MSCs in kidney disease recovery, differentiation, and microenvironment. The therapeutic efficacy and current applications of MSC-based kidney disease therapies are also discussed.
Keywords: acute and chronic kidney disease; exosome; mesenchymal stem cells; natural products.
Conflict of interest statement
The authors declare no conflicts of interest. The funding body had no role in the study design, data collection or analysis, the decision to publish, or preparation of the manuscript.
Figures
References
-
- Lentine K.L., Kasiske B.L., Levey A.S., Adams P.L., Alberu J., Bakr M.A., Gallon L., Garvey C.A., Guleria S., Li P.K., et al. Summary of kidney disease: Improving global outcomes (kdigo) clinical practice guideline on the evaluation and care of living kidney donors. Transplantation. 2017;101:1783–1792. doi: 10.1097/TP.0000000000001770. - DOI - PMC - PubMed
-
- Susantitaphong P., Cruz D.N., Cerda J., Abulfaraj M., Alqahtani F., Koulouridis I., Jaber B.L., Acute Kidney Injury Advisory Group of the American Society of Nephrology World incidence of aki: A meta-analysis. Clin. J. Am. Soc. Nephrol. 2013;8:1482–1493. doi: 10.2215/CJN.00710113. - DOI - PMC - PubMed
-
- Rahman M., Shad F., Smith M.C. Acute kidney injury: A guide to diagnosis and management. Am. Fam. Phys. 2012;86:631–639. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
